Cocrystal Pharma starts Phase 1b human challenge trial of norovirus drug CDI-988

Reuters04-01

<a href="https://laohu8.com/S/COCP">Cocrystal Pharma</a> starts Phase 1b human challenge trial of norovirus drug CDI-988

Cocrystal Pharma reported FY 2025 results while starting Phase 1b randomized, double-blind, placebo-controlled human challenge trial of oral norovirus candidate CDI-988 at Emory University School of Medicine.
First cohort is underway to confirm infectivity of GII.2 challenge strain, with later cohorts set to receive CDI-988 or placebo.
Trial will evaluate whether CDI-988 can lower likelihood of symptomatic illness, with additional readouts on viral shedding, disease severity, safety, pharmacokinetics.
Phase 1 safety and tolerability results were already presented in August 2025, supporting continued clinical development.
Program targets market with no approved norovirus treatments or vaccines, with global economic burden estimated at USD 60 billion annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624559544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624559544","market":"us","top_or_hot":-1,"title":"Cocrystal Pharma starts Phase 1b human challenge trial of norovirus drug CDI-988","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> starts Phase 1b human challenge trial of norovirus drug CDI-988\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cocrystal Pharma reported FY 2025 results while starting Phase 1b randomized, double-blind, placebo-controlled human challenge trial of oral norovirus candidate CDI-988 at Emory University School of Medicine.\n        </li>\n<li>\n          First cohort is underway to confirm infectivity of GII.2 challenge strain, with later cohorts set to receive CDI-988 or placebo.\n        </li>\n<li>\n          Trial will evaluate whether CDI-988 can lower likelihood of symptomatic illness, with additional readouts on viral shedding, disease severity, safety, pharmacokinetics.\n        </li>\n<li>\n          Phase 1 safety and tolerability results were already presented in August 2025, supporting continued clinical development.\n        </li>\n<li>\n          Program targets market with no approved norovirus treatments or vaccines, with global economic burden estimated at USD 60 billion annually.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cocrystal Pharma starts Phase 1b human challenge trial of norovirus drug CDI-988</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCocrystal Pharma starts Phase 1b human challenge trial of norovirus drug CDI-988\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 06:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> starts Phase 1b human challenge trial of norovirus drug CDI-988\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cocrystal Pharma reported FY 2025 results while starting Phase 1b randomized, double-blind, placebo-controlled human challenge trial of oral norovirus candidate CDI-988 at Emory University School of Medicine.\n        </li>\n<li>\n          First cohort is underway to confirm infectivity of GII.2 challenge strain, with later cohorts set to receive CDI-988 or placebo.\n        </li>\n<li>\n          Trial will evaluate whether CDI-988 can lower likelihood of symptomatic illness, with additional readouts on viral shedding, disease severity, safety, pharmacokinetics.\n        </li>\n<li>\n          Phase 1 safety and tolerability results were already presented in August 2025, supporting continued clinical development.\n        </li>\n<li>\n          Program targets market with no approved norovirus treatments or vaccines, with global economic burden estimated at USD 60 billion annually.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLc9w6XK:1","article_id":"2624559544","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624559544","pubTimestamp":1774996239,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cocrystal Pharma reported FY 2025 results while starting Phase 1b randomized, double-blind, placebo-controlled human challenge trial of oral norovirus candidate CDI-988 at Emory University School of Medicine.First cohort is underway to confirm infectivity of GII.2 challenge strain, with later cohorts set to receive CDI-988 or placebo.Trial will evaluate whether CDI-988 can lower likelihood of symptomatic illness, with additional readouts on viral shedding, disease severity, safety, pharmacokinetics.Phase 1 safety and tolerability results were already presented in August 2025, supporting continued clinical development.Program targets market with no approved norovirus treatments or vaccines, with global economic burden estimated at USD 60 billion annually.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","COCP":"Cocrystal Pharma, Inc."},"translate_title":"Cocrystal Pharma启动诺如病毒药物CDI-988的1b期人体攻击试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COCP":0.9},"content_text":"Cocrystal Pharma starts Phase 1b human challenge trial of norovirus drug CDI-988\n    \n\n\n          Cocrystal Pharma reported FY 2025 results while starting Phase 1b randomized, double-blind, placebo-controlled human challenge trial of oral norovirus candidate CDI-988 at Emory University School of Medicine.\n        \n\n          First cohort is underway to confirm infectivity of GII.2 challenge strain, with later cohorts set to receive CDI-988 or placebo.\n        \n\n          Trial will evaluate whether CDI-988 can lower likelihood of symptomatic illness, with additional readouts on viral shedding, disease severity, safety, pharmacokinetics.\n        \n\n          Phase 1 safety and tolerability results were already presented in August 2025, supporting continued clinical development.\n        \n\n          Program targets market with no approved norovirus treatments or vaccines, with global economic burden estimated at USD 60 billion annually.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624559544","isCrawlerRequest":true}